71 assets in Large B-Cell Lymphoma

Therapeutic assets addressing Large B-Cell Lymphoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
eb103 Large B-Cell Lymphoma	Estrella Biopharma, Inc.	P1/2	CC (43)
gfh009 Large B-Cell Lymphoma	Genfleet Therapeutics (Shanghai) Inc.	P1/2	CC (43)
Ibrutinib Large B-Cell Lymphoma	Novartis Pharmaceuticals	P1/2	CC (43)
Rhdnase I Large B-Cell Lymphoma	Tel-Aviv Sourasky Medical Center	P1	CC (43)
Sonrotoclax Large B-Cell Lymphoma	Ruijin Hospital	P1/2	CC (43)
Vnx-101 Large B-Cell Lymphoma	Vironexis Biotherapeutics Inc.	P1/2	CC (43)
1928z1xx trac t cell Large B-Cell Lymphoma	Memorial Sloan Kettering Cancer Center	P1	C (39)
cd22 car-t Large B-Cell Lymphoma	Stanford University	P1	C (39)
Efineptakin Alfa Large B-Cell Lymphoma	Washington University School of Medicine	P1	C (39)
Fctx-Cl19-1 Large B-Cell Lymphoma	FamiCordTx	P1	C (39)
Jwcar201 Large B-Cell Lymphoma	RenJi Hospital	P1	C (39)
nkx019 Large B-Cell Lymphoma	Nkarta, Inc.	P1	C (39)
sc262 Large B-Cell Lymphoma	Sana Biotechnology	P1	C (39)
Sirolimus Large B-Cell Lymphoma	Nanjing IASO Biotechnology Co., Ltd.	P1	C (39)
Stk-009 Large B-Cell Lymphoma	Synthekine	P1	C (39)
Syncar-001 Large B-Cell Lymphoma	Synthekine	P1	C (39)
Synkir-310 Large B-Cell Lymphoma	Verismo Therapeutics	P1	C (39)
Ub-Vv400 Large B-Cell Lymphoma	Nanjing IASO Biotechnology Co., Ltd.	P1	C (39)
Magrolimab Large B-Cell Lymphoma	M.D. Anderson Cancer Center	P2	C (36)
cd19x car-t Large B-Cell Lymphoma	Institute of Hematology & Blood Diseases Hospital, China	P1/2	NR ()

Showing 51 to 71 of 71 assets

PreviousPage 2 of 2Next